<DOC>
	<DOCNO>NCT01699061</DOCNO>
	<brief_summary>The purpose study determine effect tivantinib QTc interval patient solid tumor</brief_summary>
	<brief_title>Effect Tivantinib QTC Interval Cancer Subjects</brief_title>
	<detailed_description>The study design estimate maximum change QTcF ( change baseline ) placebo multiple-dose tivantinib . A tivantinib oral dose 360 mg BID select study high dose currently evaluate clinical study .</detailed_description>
	<criteria>Subjects must histologically cytologically confirm advanced solid tumor Screening Male female great equal 18 year age Women childbearing potential must negative pregnancy test perform prior start study drug Subjects ( male female ) childbearing potential must agree use double barrier contraceptive measure avoid intercourse study 90 day last dose study drug . In addition , female subject childbearing potential must negative pregnancy test result initiate study treatment An Eastern Cooperative Oncology Group ( ECOG ) performance status less equal 2 Adequate bone marrow liver function , define : Platelet count great equal 100 × 109/L Hemoglobin great equal 9.0 g/dL Absolute neutrophil count great equal 1.5 × 109/L Total bilirubin less equal 1.5 × upper limit normal ( ULN ) Alanine aminotransferase aspartate aminotransferase less equal 3 × ULN ( less equal 5 × ULN subject liver metastasis ) Serum creatinine less equal 1.5 × ULN Electrolytes within normal limit , particularly potassium , magnesium , &amp; calcium . Supplementation permit need Subjects able provide write informed consent , comply protocol visit procedure , able take oral medication , active infection chronic comorbidity would interfere therapy Subjects must fully inform illness investigational nature study protocol ( include foreseeable risk possible side effect ) must sign date IRBapproved ICF ( include HIPAA authorization , applicable ) performance studyspecific procedure test History cardiac disease : Active coronary artery disease , define myocardial infarction , unstable angina , coronary bypass graft , stenting within 6 month prior study entry Evidence uncontrolled bradycardia cardiac arrhythmia define great equal Grade 2 accord National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) , version 4 , uncontrolled hypertension Any follow ECG finding : PR interval great 240 msec less equal 110 msec bradycardia define sinus rate &lt; 50 beat per minute Mean QTcF interval great 450 msec triplicate centrally read Screening ECGs Cardiac conduction abnormality denote follow : evidence seconddegree ( type II ) thirddegree atrioventricular block , evidence ventricular preexcitation , ECG evidence complete leave bundle branch block , intraventricular conduction delay QRS duration great 120 msec , atrial fibrillation , presence cardiac pacemaker Personal family history longQT syndrome Active , clinically serious infection define great equal Grade 2 accord NCI CTCAE , version 4 Known metastatic brain meningeal tumor , unless subject great 3 month definitive therapy clinically stable ( supportive therapy steroid anticonvulsant medication allow ) respect tumor time first dose study drug Pregnant breastfeeding Any major surgical procedure within 3 week prior first dose study drug Significant gastrointestinal disorder , opinion Principal Investigator ( eg , Crohn 's disease , ulcerative colitis , extensive gastric resection , comorbid disease cause malabsorption drug ) Received tivantinib prior therapy Received anticancer therapy , include antibody , retinoid , hormonal treatment ( except megestrol acetate supportive care ) , radiation , within 3 week dose . Prior concurrent use hormone replacement therapy , use gonadotropinreleasing hormone modulators prostate cancer , use somatostatin analog neuroendocrine tumor permit Any investigational drug within 3 week prior dose Substance abuse medical , psychological , social condition may , opinion Investigator , interfere subject 's participation clinical study evaluation clinical study result Any condition unstable could jeopardize safety subject subject 's protocol compliance , include know infection human immunodeficiency virus , hepatitis B virus , hepatitis C virus Inability swallow oral medication could interfere absorption tivantinib Administration possibility initiate continue treatment know CYP 3A4 CYP2C19 enzyme Pglycoprotein alter drug ( inducer inhibitor ) nondrug agent gastric pH modifier within 14 day prior dose and/or PK evaluation ( 14 15 day ) initiation study treatment Subjects clinical diagnosis hepatic impairment and/or hepatocellular carcinoma and/or chronic liver cirrhosis confirmation either previous biopsy finding ultrasound , compute tomography ( CT ) MRI consistent chronic liver cirrhosis Subjects treatment receive drug may affect QTc ( eg , quinidine moxifloxacin )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>